{"id":"csii-followed-by-met","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Gastrointestinal disturbance (metformin)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5783405","moleculeType":null,"molecularWeight":"528.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a treatment regimen combining continuous subcutaneous insulin infusion (an insulin pump delivering basal and bolus insulin) with subsequent metformin therapy. The approach uses intensive insulin delivery initially, followed by addition of metformin, which reduces hepatic glucose production and improves peripheral insulin sensitivity. This sequential combination aims to optimize glycemic control while potentially reducing overall insulin requirements.","oneSentence":"CSII (continuous subcutaneous insulin infusion) followed by metformin sequentially delivers insulin and then enhances insulin sensitivity to manage blood glucose in diabetes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:21:39.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03194945","phase":"PHASE4","title":"Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-11-01","conditions":"Type 2 Diabetes Mellitus","enrollment":412},{"nctId":"NCT02006836","phase":"NA","title":"Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2013-01","conditions":"Diabetes","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CSII+Met"],"phase":"marketed","status":"active","brandName":"CSII followed by MET","genericName":"CSII followed by MET","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CSII (continuous subcutaneous insulin infusion) followed by metformin sequentially delivers insulin and then enhances insulin sensitivity to manage blood glucose in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}